Treatment response
The ACR20 response rate was 50.0% (95% CI 36.1–63.9%). In the
subgroup analysis based on changing dose, the ACR20 response
rate was 45.8% in patients whose dose was increased to
2.0 mg/day and 53.3% in the group maintained on 1.5 mg/day.
The overall ACR20 success rate was 46.3% (95% CI
32.6–60.4%). The ACR50 response rate was 18.5% (95% CI
9.3–31.4%). The efficacy of tacrolimus treatment was highly
significant for all individual ACR component scores compared
with baseline (P